Search results
Results from the WOW.Com Content Network
FM in the context of chemotherapy means a chemotherapy regimen used as first-line therapy in indolent lymphomas. In combination with rituximab it is called R-FM or RFM or FM-R or FMR. The [R]-FM regimen consists of: ituximab - an anti-CD20 monoclonal antibody that is able to kill both normal B cells and malignant ones; ludarabine - an ...
EPOCH is an intensive chemotherapy regimen intended for treatment of aggressive non-Hodgkin's lymphoma. [1] [2] It is often combined with rituximab. In this case it is called R-EPOCH or EPOCH-R. The R-EPOCH regimen consists of: Rituximab: an anti-CD20 monoclonal antibody, which has the ability to kill B cells, be they normal or malignant;
In order to develop more effective first-line chemotherapy regimen for aggressive lymphomas, some researchers tried to add toposide to the standard [R]-CHOP regimen. [7] There were also attempts to further improve the efficacy of the [R]-CHOEP regimen with escalating the chemotherapy doses. This mode was called [R]-High-CHOEP. However, it did ...
MOPP was the first combination chemotherapy brought in that achieved a high success rate. It was developed at the National Cancer Institute in the 1960s by a team that included Vincent DeVita, Jr. Although no longer the most effective combination, MOPP is still used after relapse or where the patient has certain allergies or lung or heart ...
A Lion in the House is a 2006 American documentary film directed by Steven Bognar and Julia Reichert [1] that explores the impact of childhood cancer on five different families throughout the span of six years in Ohio. [1]
DHAP in context of chemotherapy is an acronym for chemotherapy regimen that is used for remission induction in cases of relapsed or refractory non-Hodgkin lymphoma and Hodgkin's lymphoma. [1] It is usually given for 2-3 courses, then followed by high-dose chemotherapy and autologous stem cell transplantation .
It was established as Clinical Lymphoma in 2000, renamed to Clinical Lymphoma & Myeloma in 2005 and obtained its current name in 2010. The journal covers research on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia, and related disorders, including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias.
Stanford V (usually spoken as Stanford Five), is a chemotherapy regimen (with accompanying Radiation therapy) intended as a first-line treatment for Hodgkin lymphoma.The regimen was developed in 1988, with the objective of maintaining a high remission rate while reducing the incidence of acute and long term toxicity, pulmonary damage, and sterility observed in alternative treatment regimens ...